objective evaluate safety visual outcomes proton therapy subfoveal neovascular macular degeneration amd design randomized clinical trial participants patients angiographic evidence classic choroidal neovascularization resulting amd visual acuity better methods patients assigned randomly NUMBER receive gray equivalent cge proton radiation NUMBER equal fractions visual acuity measured using standardized protocol refraction complete ophthalmological examinations color fundus photography fluorescein angiography performed NUMBER NUMBER NUMBER NUMBER NUMBER months treatment main outcome measure proportion eyes losing NUMBER lines vision baseline statistics used compare cumulative rates vision loss NUMBER treatment groups results NUMBER months treatment NUMBER eyes NUMBER NUMBER eyes NUMBER lost NUMBER lines vision groups respectively rates increased NUMBER group NUMBER group NUMBER months treatment p NUMBER radiation complications developed NUMBER patients receiving NUMBER cge NUMBER patients receiving NUMBER cge conclusions significant differences rates visual loss NUMBER dose groups proton radiation useful adjuvant therapy alternative patients decline appropriate approved therapies age related dose ranging best corrected NUMBER cobalt NUMBER cge kaplan meier NUMBER cge NUMBER cge NUMBER cge NUMBER cge NUMBER NUMBER